Studies

131 studies · Download as JSON

• Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Benefit
• Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetesRandomized trial · 2026 · Study tier 3 · Different population · Unclear
• Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trialRandomized trial · 2026 · Study tier 2 · Different population · Mixed · Partly industry funded
• Tirzepatide for the treatment of obstructive sleep apnea: from apnea-hypopnea index reduction to cardiometabolic risk mitigation-a narrative reviewRandomized trial · 2026 · Not yet reviewed
• Semaglutide, Tirzepatide and Clinically Recorded Alcohol-Related Outcomes in Type 2 Diabetes: A Target Trial EmulationRetrospective cohort · 2026 · Not yet reviewed
• The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agentsMeta-analysis · 2026 · Not yet reviewed
• PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-TirzepatideCell / in-vitro · 2026 · Not yet reviewed
• Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World CohortRetrospective cohort · 2026 · Study tier 4 · Partial match · Unclear
• Combined time-restricted feeding and resistance training enhance tirzepatide-induced improvements in adiposity and whole-body insulin sensitivity in female miceAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit
• Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Different population · Mixed
• Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERSPharmacovigilance · 2026 · Study tier 4 · Population unclear · Mixed
• Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12-Month Real-World ResultsRetrospective cohort · 2026 · Facts auto-extracted
• Oral Health-Related Adverse Events of GLP-1 Receptor AgonistsPharmacovigilance · 2026 · Study tier 4 · Population unclear · Harm direction
• GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysisRetrospective cohort · 2026 · Facts auto-extracted
• Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or ObesitySystematic review · 2026 · Not rated · Different population · Null
• How Well Are We Measuring Nausea? A Narrative Review of Patient-Reported Outcome Gaps in GLP-1 Receptor Agonist Obesity TrialsPharmacovigilance · 2026 · Facts auto-extracted
• Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing ControversiesPharmacovigilance · 2026 · Facts auto-extracted
• Adverse oral effects of GLP-1 and GIP receptor agonists: a scoping review protocolPharmacovigilance · 2026 · Facts auto-extracted
• Pulmonary Aspiration and Related Outcomes Associated with Semaglutide and Tirzepatide: A Comparative Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)Pharmacovigilance · 2026 · Not peer reviewed · Facts auto-extracted
• Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatideRetrospective cohort · 2026 · Facts auto-extracted
• GLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort studyRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit
• Glucagon-Like Peptide-1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and ObesityRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit
• Urinary Stone Recurrence After Initiation of GLP-1-Based Therapy: A Romanian Retrospective Cohort Study of Clinical, Renal, and Hydration-Related FactorsRetrospective cohort · 2026 · Facts auto-extracted
• Biliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 InhibitorsRetrospective cohort · 2026 · Facts auto-extracted
• Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World CohortRetrospective cohort · 2026 · Study tier 4 · Different population · Unclear
• Weight-Loss Magnitude, Fat Mass, and Device-Estimated Muscle Mass Loss During Obesity PharmacotherapyRetrospective cohort · 2026 · Facts auto-extracted
• GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?Narrative review · 2026 · Not rated · Population unclear · Mixed
• Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Benefit
• Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity MedicationsRetrospective cohort · 2026 · Preliminary · Population unclear · Unclear · Not peer reviewed
• Body Weight Changes and Exploratory Metabolic Outcomes During Semaglutide and Tirzepatide Treatment: A Real-World Longitudinal Cohort Study from TürkiyeProspective cohort · 2026 · Facts auto-extracted
• Tirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case seriesCase series · 2026 · Study tier 4 · Different population · Unclear
• Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndromeRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit
• Exploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanismsNarrative review · 2026 · Not rated · Partial match · Benefit
• Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic ReviewSystematic review · 2026 · Not rated · Population unclear · Unclear
• Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signalingAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit
• Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort StudyRetrospective cohort · 2026 · Study tier 3 · Different population · Mixed
• Adverse Oral and Salivary Effects Associated With Glucagon-Like Peptide-1 Receptor Agonists: Clinical InsightsNarrative review · 2026 · Not rated · Different population · Unclear
• GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Mixed
• GLP-1 Receptor Agonists and Dual GIP/GLP-1 and Reduction in Major Cardiovascular Events: A Systematic Review and Network Meta-AnalysisSystematic review · 2026 · Not rated · Different population · Unclear · Not peer reviewed
• Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical PracticeRetrospective cohort · 2026 · Preliminary · Different population · Unclear · Not peer reviewed
• Tirzepatide attenuates cardiac microvascular injury and ferroptosis-related lipid peroxidation in diabetic mice: endothelial responses in the context of partial PRKN silencingAnimal study · 2026 · Facts auto-extracted
• Semaglutide and Tirzepatide Suppress Hepatic Fatty Acid Uptake and Fatty Acid β-Oxidation in High-Fat Diet-Induced Obesity MiceAnimal study · 2026 · Facts auto-extracted
• Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issuesPharmacovigilance · 2026 · Facts auto-extracted
• Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Different population · Benefit
• A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin TherapyMeta-analysis · 2026 · Facts auto-extracted
• Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head StudiesMeta-analysis · 2026 · Study tier 2 · Different population · Mixed
• Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agentsPharmacovigilance · 2026 · Facts auto-extracted
• Diabetic Retinal Disease Onset and Progression During Established Semaglutide or Tirzepatide Treatment: A Retrospective Comparative Cohort Study With a Descriptive Regional Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) ReviewRetrospective cohort · 2026 · Facts auto-extracted
• Non-ST Elevation Myocardial Infarction Following Significant Weight Loss During Tirzepatide Therapy: A Case ReportPharmacovigilance · 2026 · Facts auto-extracted
• Increasing Direct-to-Consumer Use of Semax and Selank Peptides Decoded from LLM-Curated Clinical Notes and Physician AdjudicationRetrospective cohort · 2026 · Not peer reviewed · Facts auto-extracted
• The dual incretin agonist tirzepatide blunts nicotine-induced behaviours and neurochemistry in male miceAnimal study · 2026 · Facts auto-extracted
• Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity RiskAnimal study · 2026 · Facts auto-extracted
• New-Onset Heart Failure in Patients with Obesity using Tirzepatide or SemaglutideRetrospective cohort · 2026 · Not peer reviewed · Facts auto-extracted
• Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesityRetrospective cohort · 2026 · Facts auto-extracted
• Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved IndicationRetrospective cohort · 2026 · Facts auto-extracted
• Future GLP-1 receptor co-agonists and their cardiac effectsAnimal study · 2026 · Facts auto-extracted
• Real-World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in FAERSPharmacovigilance · 2026 · Facts auto-extracted
• Prior GLP-1RA or Tirzepatide Use and Early Cardiorenal Outcomes After Metabolic and Bariatric SurgeryRetrospective cohort · 2026 · Facts auto-extracted
• Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoringPharmacovigilance · 2026 · Facts auto-extracted
• Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With ObesityRetrospective cohort · 2026 · Facts auto-extracted
• GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-AnalysisMeta-analysis · 2026 · Facts auto-extracted
• Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysisRetrospective cohort · 2026 · Facts auto-extracted
• Combination of genetic eNOS deficiency and high-fat diet induces reproducible cardiometabolic HFpEFAnimal study · 2026 · Facts auto-extracted
• Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched studyRetrospective cohort · 2026 · Facts auto-extracted
• Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Facts auto-extracted
• The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysisMeta-analysis · 2026 · Facts auto-extracted
• Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese miceAnimal study · 2026 · Not peer reviewed · Facts auto-extracted
• GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort studyRetrospective cohort · 2026 · Facts auto-extracted
• Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping StudyPharmacovigilance · 2026 · Facts auto-extracted
• Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic ReactionsPharmacovigilance · 2026 · Facts auto-extracted
• The GLP-1 Nutritional Paradox: A Global Meta-Analysis of Sarcopenic Risks and Micronutrient Gaps in the Post-Obesity EraMeta-analysis · 2026 · Not peer reviewed · Facts auto-extracted
• Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication OpportunitiesRetrospective cohort · 2026 · Not peer reviewed · Facts auto-extracted
• Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implicationsRetrospective cohort · 2026 · Facts auto-extracted
• Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation StudyPharmacovigilance · 2026 · Facts auto-extracted
• Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic ReviewSystematic review · 2026 · Facts auto-extracted
• Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical TrialsMeta-analysis · 2026 · Facts auto-extracted
• Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USARetrospective cohort · 2026 · Facts auto-extracted
• Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-AnalysisMeta-analysis · 2026 · Facts auto-extracted
• Musculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting SystemPharmacovigilance · 2026 · Facts auto-extracted
• Ischemic Colitis in the Setting of Tirzepatide Use: A Potentially Underrecognized Adverse EffectPharmacovigilance · 2026 · Facts auto-extracted
• Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSARandomized trial · 2026 · Facts auto-extracted
• FDA prescribing information: Zepbound, ZEPBOUND (TIRZEPATIDE) - label effective 2026-08-28Regulatory document · 2026 · Not peer reviewed · Facts auto-extracted
• Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetesRetrospective cohort · 2026 · Facts auto-extracted
• Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc AnalysisRandomized trial · 2026 · Facts auto-extracted
• Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic ReviewSystematic review · 2026 · Facts auto-extracted
• Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response EvidenceSystematic review · 2026 · Facts auto-extracted
• Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life OutcomesSystematic review · 2026 · Facts auto-extracted
• Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity ReactionsPharmacovigilance · 2026 · Facts auto-extracted
• Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled TrialRandomized trial · 2026 · Facts auto-extracted
• Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trialRandomized trial · 2026 · Facts auto-extracted
• Long-Term Clinical Outcomes and Real-World Effectiveness of Tirzepatide in Adults With Overweight or Obesity: A Systematic ReviewSystematic review · 2026 · Facts auto-extracted
• Comparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS databasePharmacovigilance · 2026 · Facts auto-extracted
• FDA prescribing information: MOUNJARO (TIRZEPATIDE) - label effective 2026-07-29Regulatory document · 2026 · Not peer reviewed · Facts auto-extracted
• Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase)Pharmacovigilance · 2026 · Facts auto-extracted
• Current status of anti-obesity medications and performance, an EHR based surveyRetrospective cohort · 2026 · Facts auto-extracted
• Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled TrialsUmbrella review · 2026 · Study tier 2 · Different population · Mixed
• Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT TrialRandomized trial · 2026 · Facts auto-extracted
• Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
• Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic ControlSystematic review · 2026 · Facts auto-extracted
• Genetic predictors of GLP1 receptor agonist weight loss and side effectsDesign unknown · 2026 · Study tier 4 · Different population · Unclear
• Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic BenefitsMeta-analysis · 2026 · Facts auto-extracted
• Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Mixed
• Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trialRandomized trial · 2026 · Facts auto-extracted
• Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Harm direction
• Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetesRetrospective cohort · 2026 · Facts auto-extracted
• Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysisMeta-analysis · 2026 · Facts auto-extracted
• Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance databasePharmacovigilance · 2026 · Facts auto-extracted
• Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysisMeta-analysis · 2026 · Facts auto-extracted
• Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trialsMeta-analysis · 2026 · Facts auto-extracted
• Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort StudyRetrospective cohort · 2026 · Facts auto-extracted
• Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort studyRetrospective cohort · 2026 · Facts auto-extracted
• Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatideRetrospective cohort · 2026 · Facts auto-extracted
• Impact of Glucagon-Like Peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) Receptor Agonists on Intraocular Pressure in Glaucoma: A Case SeriesCase series · 2026 · Facts auto-extracted
• Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic reviewSystematic review · 2026 · Facts auto-extracted
• Pancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reportsPharmacovigilance · 2026 · Facts auto-extracted
• Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort studyRetrospective cohort · 2026 · Facts auto-extracted
• Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With ObesityRetrospective cohort · 2026 · Facts auto-extracted
• Pancreatic and Gallbladder Adverse Events Associated with Tirzepatide in Obesity Management: A Scoping ReviewPharmacovigilance · 2026 · Facts auto-extracted
• Management of Obesity in Special Populations and Limited-Resource Settings: An Egyptian Medical Position StatementGuideline · 2026 · Not yet reviewed
• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesRandomized trial · 2025 · Study tier 1 · Different population · Mixed · Industry funded
• Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT TrialRandomized trial · 2025 · Facts auto-extracted
• Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2025 · Study tier 2 · Different population · Unclear
• The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysisRetrospective cohort · 2025 · Study tier 3 · Partial match · Benefit
• Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trialRandomized trial · 2025 · Facts auto-extracted
• Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
• Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysisMeta-analysis · 2025 · Study tier 3 · Different population · Unclear
• Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trialsMeta-analysis · 2025 · Study tier 2 · Population unclear · Mixed
• Tirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityTwo phase 3, double-blind, randomized, controlled trials under one master protocol; parallel-arm, placebo-controlled, 52-week treatment duration; trial 1 (gpi1, not on pap) and trial 2 (gpi2, on pap). · 2024 · Study tier 2 · Different population · Benefit · Industry funded
• Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategiesNarrative review · 2024 · Not rated · Population unclear · Mixed
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical TrialRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Industry funded
• The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysisRandomized trial · 2022 · Study tier 3 · Different population · Mixed · Industry funded